Moreover, CD8+ and CD4+ T-cell densities in the tumour were identified as the two most optimised predictive biomarkers, consistent with observations by studies on single-agent PD-L1 blockade therapies [20,21]. This evidence concerns the gene CD4 and neoplasm.